Skip to main content
Caplight Logo









PridCor Therapeutics

PridCor Therapeutics

Private
Tuscaloosa, AlabamaHealthcare & Life Scienceshttps://pridcor.com/

Last Round

Early Stage

VC

May 8, 2026

Momentum

Top 50%

of companies Caplight tracks

Company Overview

PridCor Therapeutics is a clinical-stage biopharmaceutical company that develops novel antiviral therapies to address infection-associated chronic illnesses, including Long COVID and other viral-driven conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

Huntington's Disease treatmentALS treatmentpridopidineneurodegenerative disease treatmentSigma-1 Receptor agonistS1R agonistneuroprotective therapyfirst-in-class drugsmall molecule drugclinical stage pharmadrug developmentbiopharmaceutical companyoral drugpharmaceutical licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PridCor Therapeutics Comparables

Compare PridCor Therapeutics with similar companies based on industry and business-model similarity.

PridCor Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Spinogenix, Inc.
77%
NeuroSense Therapeutics
74%
Anavex Life Sciences
67%

PridCor Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early Stage VCMay 8, 2026

Key People

Founding team and executive leadership

William Pridgen

Chief Executive Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 8, 2026

    Raised an Early Stage VC round.

Recent news

Latest coverage and updates

  • partners_withSep 24, 2026

    PridCor Therapeutics, LLC partnered with Icahn School of Medicine at Mount Sinai on Sep 24th '26.

PridCor Therapeutics Filings

Explore SEC and related filing metadata, where available.

PridCor Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about PridCor Therapeutics's valuation, stock price, and market status.

Is PridCor Therapeutics a public or private company?

PridCor Therapeutics is a private company.

What is the current stock price of PridCor Therapeutics?

PridCor Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is PridCor Therapeutics worth (valuation)?

Valuation information for PridCor Therapeutics is not publicly available.

Can I buy PridCor Therapeutics stock?

PridCor Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was PridCor Therapeutics's last funding round?

PridCor Therapeutics's most recent funding round was Early Stage VC on May 8, 2026.

Who are the main investors in PridCor Therapeutics?

Investor information for PridCor Therapeutics is not publicly disclosed.

Will PridCor Therapeutics IPO soon?

No public IPO plans have been announced for PridCor Therapeutics.

How can I track PridCor Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor PridCor Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTuscaloosa, Alabama
Employee Range2
Year Founded2025
Last FundingMay 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?